PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 30, 2011European Journal of Heart Failure213 citationsOpen Access

Can Emerging Biomarkers of Myocardial Remodelling Identify Asymptomatic Hypertensive Patients at Risk for Diastolic Dysfunction and Diastolic Heart Failure?

View Full Paper
PCPatrick CollierCardio-OncologyCWChris WatsonHeart Failure & TransplantVVVictor VoonHomerton University Hospital

Structured PICO

Do fibro-inflammatory biomarkers identify asymptomatic hypertensive patients at risk for diastolic dysfunction and HFpEF?

P
Population
275 stable hypertensive patients, divided into asymptomatic hypertension (n=94, further subdivided by left atrial volume index ≥34 mL/m² [n=30] and <34 mL/m² [n=64]) and heart failure with preserved ejection fraction (n=181).
I
Intervention
Measurement of fibro-inflammatory biomarkers (IL6, IL8, MCP1, TNFα, collagen 1 and 3 markers, MMP2, MMP9, TIMP1, BNP)
C
Comparator
Comparison between asymptomatic hypertension and HFpEF, and within asymptomatic hypertension based on left atrial volume index
O
Outcome
Levels of fibro-inflammatory biomarkers across stages of hypertensive heart diseasesurrogate

Fibro-inflammatory biomarkers, particularly MMP9 and TIMP1, vary across stages of hypertensive heart disease and may help identify asymptomatic patients at risk for progression to heart failure.

Abstract

AIMS: Hypertension is one of the main drivers of the heart failure (HF) epidemic. The aims of this study were to profile fibro-inflammatory biomarkers across stages of the hypertensive heart disease (HHD) spectrum and to examine whether particular biochemical profiles in asymptomatic patients identify a higher risk of evolution to HF. METHODS AND RESULTS: This was a cross-sectional observational study involving a population of 275 stable hypertensive patients divided into two different cohorts: Group 1, asymptomatic hypertension (AH) (n= 94); Group 2, HF with preserved ejection fraction (n= 181). Asymptomatic hypertension patients were further subdivided according to left atrial volume index ≥34 mL/m(2) (n= 30) and <34 mL/m(2) (n= 64). Study assays involved inflammatory markers interleukin 6 (IL6), interleukin 8 (IL8), monocyte chemoattractant protein 1 (MCP1), and tumour necrosis factor α, collagen 1 and 3 metabolic markers carboxy-terminal propeptide of collagen 1, amino-terminal propeptide of collagen 1, amino-terminal propeptide of collagen 3 (PIIINP), and carboxy-terminal telopeptide of collagen 1 (CITP), extra-cellular matrix turnover markers matrix metalloproteinase 2 (MMP2), matrix metalloproteinase 9 (MMP9), and tissue inhibitor of metalloproteinase 1 (TIMP1), and the brain natriuretic peptide. Data were adjusted for age, sex, systolic blood pressure, and creatinine. Heart failure with preserved ejection fraction was associated with an increased inflammatory signal (IL6, IL8, and MCP1), an increased fibrotic signal (PIIINP and CITP), and an increased matrix turnover signal (MMP2 and MMP9). Alterations in MMP and TIMP enzymes were found to be significant indicators of greater degrees of asymptomatic left ventricular diastolic dysfunction. CONCLUSION: These data define varying fibro-inflammatory profiles throughout different stages of HHD. In particular, the observations on MMP9 and TIMP1 raise the possibility of earlier detection of those at risk of evolution to HF which may help focus effective preventative strategies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Collier et al. (2011) studied this question.

synapsesocial.com/papers/69f3ee0edc238f81977995a0https://doi.org/10.1093/eurjhf/hfr079
Ask AI
Helpful
Bookmark
Share
View Full Paper